Bronchodilator effects of indacaterol and formoterol in patients with COPD

被引:36
作者
Beier, J. [1 ]
Beeh, K. -M. [1 ]
Brookman, L. [2 ]
Peachey, G. [2 ]
Hmissi, A. [3 ]
Pascoe, S. [2 ]
机构
[1] Insaf Resp Res Inst, D-65187 Wiesbaden, Germany
[2] Novartis Horsham Res Ctr, Horsham, W Sussex, England
[3] Novartis Pharma AG, Basel, Switzerland
关键词
Bronchodilation; Chronic obstructive pulmonary disease; Forced expiratory volume in 1 s; Formoterol; Indacaterol; Inspiratory capacity; OBSTRUCTIVE PULMONARY-DISEASE; EXERCISE PERFORMANCE; INSPIRATORY CAPACITY; LUNG HYPERINFLATION; TIOTROPIUM; DYSPNEA; REVERSIBILITY; SPIROMETRY; SALMETEROL; TOLERANCE;
D O I
10.1016/j.pupt.2009.05.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Resting inspiratory capacity (IC) reflects static hyperinflation in chronic obstructive pulmonary disease (COPD). This study compared the effects of formoterol and indacaterol, a novel once-daily ultra-long-acting beta(2)-agonist (or ultra-LABA), on resting IC and forced expiratory volume in 1 s (FEV(1)). Methods: Thirty patients with COPD (mean FEV(1)/FVC 0.49, mean FEV(1) 56% predicted) each inhaled three treatments (two in randomized sequence followed by open-label formoterol) on separate study days: a single dose of indacaterol 300 mu g, matching placebo, and two doses of formoterol 12 mu g 12 h apart. Results: Indacaterol and formoterol increased FEV(1) and IC at all time points relative to placebo (p < 0.001). Peak effects on FEV(1) were similar, while indacaterol had a greater effect on peak IC (31% vs 23% from pre-dose; p=0.034). Indacaterol had a greater effect than formoterol on FEV(1) at 8 h (1.47 vs 1.39 L; p=0.014) and 24 h (1.44 vs 1.35 L; p=0.003), and on IC from 4 to 24 h (differences of 0.13-0.19 L; p < 0.05). At 24 h, indacaterol and formoterol increased FEV(1) by 17.7% and 7.5%, respectively, from pre-dose. Conclusions: This study discriminated between the effects on IC and FEV(1) of once daily indacaterol and twice daily formoterol. The greater effect of indacaterol on IC may translate into improved long-term clinical outcomes. (c) 2009 Published by Elsevier Ltd.
引用
收藏
页码:492 / 496
页数:5
相关论文
共 19 条
  • [1] Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD:: A 28-day randomised, placebo controlled clinical trial
    Beier, Jutta
    Chanez, Pascal
    Martinot, Jean-Benoit
    Schreurs, A. J. M.
    Tkacova, Ruzena
    Bao, Weibin
    Jack, Damon
    Higgins, Mark
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (06) : 740 - 749
  • [2] Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest
    Boni, E
    Corda, L
    Franchini, D
    Chiroli, P
    Damiani, GP
    Pini, L
    Grassi, V
    Tantucci, C
    [J]. THORAX, 2002, 57 (06) : 528 - 532
  • [3] Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility
    Bouros, D
    Kottakis, J
    Le Gros, V
    Overend, T
    Della Cioppa, G
    Siafakas, N
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (05) : 581 - 586
  • [4] Bronchodilator reversibility testing in chronic obstructive pulmonary disease
    Calverley, PMA
    Burge, PS
    Spencer, S
    Anderson, JA
    Jones, PW
    [J]. THORAX, 2003, 58 (08) : 659 - 664
  • [5] Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes
    Celli, B
    ZuWallack, R
    Wang, S
    Kesten, S
    [J]. CHEST, 2003, 124 (05) : 1743 - 1748
  • [6] Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD
    Di Marco, F
    Milic-Emili, J
    Boveri, B
    Carlucci, P
    Santus, P
    Casanova, F
    Cazzola, M
    Centanni, S
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (01) : 86 - 94
  • [7] *GOLD, APR 1998 NHLBI WHO W
  • [8] The role of spirometry in evaluating therapeutic responses in advanced COPD
    Laveneziana, Pierantonio
    O'Donnell, Denis E.
    [J]. DISEASE MANAGEMENT & HEALTH OUTCOMES, 2007, 15 (02) : 91 - 100
  • [9] Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD
    Maltais, F
    Hamilton, A
    Marciniuk, D
    Hernandez, P
    Sciurba, FC
    Richter, K
    Kesten, S
    O'Donnell, D
    [J]. CHEST, 2005, 128 (03) : 1168 - 1178
  • [10] Standardisation of spirometry
    Miller, MR
    Hankinson, J
    Brusasco, V
    Burgos, F
    Casaburi, R
    Coates, A
    Crapo, R
    Enright, P
    van der Grinten, CPM
    Gustafsson, P
    Jensen, R
    Johnson, DC
    MacIntyre, N
    McKay, R
    Navajas, D
    Pedersen, OF
    Pellegrino, R
    Viegi, G
    Wanger, J
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (02) : 319 - 338